The findings hint at why the AβYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients.

Relying on iFR/FFR values from the LCx alone could mean many patients with left main disease miss out on revascularization.

Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic ...

Citing a low hemorrhage rate and other issues, one expert says the results should be replicated before changing practice.

OCT seems to reduce periprocedural MI, a benefit not seen in the chronic coronary syndrome patients that deserves further ...

HELSINKI, Finland—It may be possible to safely cut back on the level of monitoring performed in select patients with acute ...

The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER ...

Researchers used PET/MRI to detect otherwise invisible inflammation. Less clear is how this might influence patient care.

This factor helps explain why the device failed to match other commercially approved devices in the IDE trial.

The free risk calculator can be incorporated into existing spreadsheets of patient data for use in heart team discussions.

A sex gap seen in quality of life deserves further scrutiny, but the DISCHARGE trial data are still reassuring, says Maros ...

The higher stroke risk appears to accrue over time, and researchers say more work is needed to better understand why.